バルビツール酸系薬剤の世界市場

バルビツール酸系薬剤の世界市場は2030年までに5億2,170万米ドルに達する見込み

2024年に4億6,480万米ドルと推定されるバルビツール酸系薬剤の世界市場は、2030年には5億2,170万米ドルに達し、分析期間2024～2030年のCAGRは1.9%で成長すると予測されます。本レポートで分析したセグメントの1つである長時間作用型医薬品は、CAGR 1.6%を記録し、分析期間終了時には2億640万米ドルに達すると予測されます。短時間作用型医薬品セグメントの成長率は、分析期間中CAGR 1.5%と推定されます。

米国市場は1億2,660万米ドルと推定、中国はCAGR 3.8%で成長予測

米国のバルビツール酸系薬剤市場は、2024年に1億2,660万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9,760万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と1.4%と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界のバルビツール酸系薬剤市場- 主要動向と促進要因のまとめ

バルビツール酸系薬剤が最新の鎮静薬の世界で依然として重要なのはなぜか？

ベンゾジアゼピン系鎮静剤や非ベンゾジアゼピン系鎮静剤のような新しいクラスの中枢神経抑制剤が出現し、広く採用されるようになったにもかかわらず、バルビツール酸系薬剤は世界中の医療行為の特定の分野で重要な役割を果たし続けています。19世紀後半に誕生したバルビツール酸系鎮静薬は、最初の合成鎮静催眠薬のひとつであり、麻酔導入、発作抑制、不眠症管理などに急速に使用されるようになりました。毒性、依存性、治療域の狭さへの懸念からバルビツール酸系薬剤の使用は著しく減少したが、特定の臨床場面では依然として不可欠です。てんかん治療において、特に低・中所得国では、フェノバルビタールは、その手頃な価格、実証された有効性、長い臨床使用の歴史から、依然として最も処方されている抗てんかん薬の一つです。バルビツール酸系抗てんかん薬は、急性発作、てんかん重積状態、および急速かつ持続的な中枢神経抑制が必要とされる重篤な医療環境における医療的昏睡の管理にも使用されています。さらに、予測可能な薬物動態と作用機序のため、薬物反応の一貫性が最も重要な状況でも有用です。発作性疾患の脳波検査などの診断場面では、脳活動を誘発または調節するためにバルビツール酸系薬剤が投与されることがあります。獣医学においても、特に安楽死処置やコンパニオンアニマルおよび家畜動物の手術における麻酔薬として、バルビツール酸系薬剤が多く使用されています。多くの疾患においてバルビツール酸系薬剤が第一選択薬ではなくなってきているとはいえ、バルビツール酸系薬剤の重要性が継続しているのは、そのユニークな薬理学的プロファイルが、より安全な代替薬があるにもかかわらず、特定の使用事例においてバルビツール酸系薬剤を代替不能なものにしていることの証左です。このような持続的な臨床的ニッチ、特に資源に制約のある環境において、世界のバルビツール酸塩市場は安定した需要を維持しています。

バルビツール酸系薬剤の規制および製造動向は何によって形成されているか？

バルビツール酸塩市場の規制・製造状況は、世界の規制強化、コスト効率の要求、医薬品製造における技術革新の重圧の下で進化しています。バルビツール酸系薬剤は、その乱用、過剰摂取、中毒の可能性が十分に立証されているため、ほとんどの法域で規制薬物に分類されています。この分類は、製造ライセンス、保管、処方制限、流通ロジスティクス、記録管理などに厳格な要件を課し、製造の複雑さとコンプライアンス・コストを増大させる。メーカー各社は、適正製造規範（GMP）の厳格な遵守を維持しつつ、規制の枠組みが整っている地域に事業を集中させることで対応しています。サプライチェーンの継続性を確保しつつオーバーヘッドを削減するため、原薬合成の受託製造やアウトソーシングの動向もあります。同時に、リアルタイムの放出試験、PAT（プロセス分析技術）、AIによるバッチモニタリングなどの高度な分析技術が一貫性を強化し、製品リコールを減少させています。安全性に関する継続的な懸念に対応するため、製薬会社は従来のバルビツール酸系薬剤の徐放性製剤や低用量製剤への改良に投資しており、血漿中ピーク濃度の低下と関連リスクの低減を目指しています。さらに、バルビツール酸系薬剤と補完的な薬剤を組み合わせて副作用を軽減するハイブリッド型薬剤開発にも、新たな関心が集まっています。各社はまた、バルビツール酸塩の足場を現代創薬化学のレンズを通して再検討し、安全性と受容体選択性を改善した類似体の開発を模索しています。これらの要因が相まって、近代化され、コンプライアンスが強化され、イノベーションに焦点を当てた生産環境が形成され、世界のバルビツール酸製剤のサプライチェーンとデリバリーチェーンが徐々に再構築されつつあります。

バルビツール酸塩のエコシステムにおける消費者層と最終用途はどのように進化しているか？

バルビツール酸系薬剤の消費者層と用途領域は、医療ニーズの変化、地理的格差、臨床診療の変化により、静かではあるがインパクトのある変容を遂げています。高所得国では、バルビツール酸塩の使用は、治療抵抗性てんかん、脳外科手術の麻酔導入、ICUの鎮静プロトコールなど、特殊な医療行為に限定されています。このような環境でバルビツール酸系薬剤を必要とする患者は、通常、神経科医、麻酔科医、重症治療専門医などの専門医の管理下にあり、管理・監視された投与が保証されています。対照的に、医療予算に制約があり、ヘルスケアのインフラが発展途上にある中低所得国では、バルビツール酸系薬剤は安価で実績があるため、依然として入手しやすく、広く使用されています。このような処方パターンの相違は、バルビツール酸塩市場の世界の広がりに影響を与える社会経済的要素を浮き彫りにしています。もう1つの発展領域は緩和ケアで、特にがん患者や神経変性疾患の患者において、難治性の疼痛や終末期の興奮を管理するためにバルビツール酸塩が使用されています。さらに、診断神経学や法医学毒物学研究室におけるバルビツール酸塩の使用拡大により、医療機関や公衆衛生システムからの安定した需要が維持されています。獣医学分野もバルビツール酸塩経済において重要な役割を担っており、家畜および農業動物の両方で人道的な安楽死および外科的鎮静ソリューションに対する世界の需要が増加しています。さらに、外科的介入を必要とする慢性疾患の増加により、即効性と信頼性の高い鎮静薬に対するニーズが高まっています。また、新たな動向として、急速な中枢神経抑制が治療上有益である可能性のある緊張病や重度の双極性激越などのニッチな精神科症例におけるバルビツール酸塩の使用法を調整することに関心が集まっています。このような地域、患者タイプ、医療分野にわたる多様な用途は、バルビツール酸系薬剤の消費者層を拡大し、再定義し続けています。

バルビツール酸系薬剤世界市場の成長を促進しているものは？

世界のバルビツール酸系薬剤市場の成長は、臨床需要パターン、エンドユーザーの嗜好、分野特有の力学に関連するいくつかの要因によって牽引されています。特に低資源国では、フェノバルビタールがその手頃な価格、入手しやすさ、信頼性の高い有効性プロファイルにより、依然として第一選択薬となっています。新しい抗てんかん薬が入手できない、あるいはコスト的に高価である市場では、バルビツール酸系薬剤が発作管理の基幹薬として、特に全般性強直間代発作を有する小児および成人患者を中心に使用されています。特に治療的昏睡の導入、頭蓋内圧の上昇の抑制、てんかん重積状態など、迅速かつ深い鎮静が必要とされる場合です。動物用医薬品市場もまた、ペットの飼育数の増加、動物の健康に対する支出の増加、動物保護施設や農場における標準化された安楽死プロトコル（バルビツール酸の使用がしばしば義務付けられている）などによって、成長に大きく寄与しています。さらに、世界の外科手術の急増、特に高齢化社会では、短時間作用型バルビツール酸塩が引き続き関連性を見出す、さまざまな鎮静オプションが必要となります。技術の進歩も市場の拡大に拍車をかけており、特に、治療効果を維持しながら従来の毒性懸念を軽減することを目的とした、徐放性製剤や低用量製剤の開発が進んでいます。新興国における規制の変化により、バルビツール酸系薬剤の承認がより取得しやすくなり、市場規模が拡大しています。さらに、特に中枢神経系疾患に対するバルビツール酸アナログの新たな治療可能性を探求する研究界の関心は、技術革新と特許活動に拍車をかけ、新たな治療の道を開く可能性があります。最後に、流通インフラの充実とデジタルサプライチェーンの統合が、入手可能性の安定化とボトルネックの解消に貢献し、ヘルスケアと獣医分野の需要を効率的に満たしています。こうした複合的な要因が、世界のバルビツール酸系薬剤市場の持続的な成長軌道を強化しています。

セグメント

医薬品（長時間作用型医薬品、短時間作用型医薬品、超短時間作用型医薬品、配合剤）;疾患タイプ（不眠症疾患、てんかん疾患、鎮静疾患、その他の疾患タイプ）;流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例（合計 47注目）

• Abbott Laboratories
• AbbVie Inc.
• Akorn Operating Company LLC
• Centurion Healthcare Pvt. Ltd.
• Eli Lilly and Company
• Ethypharm
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson
• Lundbeck A/S
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Mylan N.V.
• Par Pharmaceutical
• Pfizer Inc.
• Samarth Life Sciences Pvt. Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

AI統合

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Barbiturate Drugs Market to Reach US$521.7 Million by 2030

The global market for Barbiturate Drugs estimated at US$464.8 Million in the year 2024, is expected to reach US$521.7 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Long-Acting Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$206.4 Million by the end of the analysis period. Growth in the Short-Acting Drugs segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$126.6 Million While China is Forecast to Grow at 3.8% CAGR

The Barbiturate Drugs market in the U.S. is estimated at US$126.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$97.6 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Barbiturate Drugs Market - Key Trends & Drivers Summarized

Why Are Barbiturates Still Relevant in a World of Modern Sedatives?

Despite the emergence and widespread adoption of newer classes of central nervous system depressants like benzodiazepines and non-benzodiazepine sedatives, barbiturate drugs continue to play a crucial role in certain areas of medical practice across the globe. Originating in the late 19th century, barbiturates were among the first synthetic sedative-hypnotics and rapidly became the drug of choice for anesthesia induction, seizure control, and insomnia management. Although their use has declined significantly due to concerns over toxicity, dependency, and narrow therapeutic margins, they remain indispensable in specific clinical scenarios. In epilepsy treatment, particularly in low- and middle-income countries, phenobarbital is still one of the most prescribed antiepileptic drugs due to its affordability, proven efficacy, and long history of clinical use. Barbiturates are also used in the management of acute seizures, status epilepticus, and in medically induced comas in critical care settings where rapid, sustained CNS depression is required. Furthermore, their predictable pharmacokinetics and mechanism of action make them valuable in situations where drug response consistency is paramount. In diagnostic settings, such as in EEG testing for seizure disorders, barbiturates are occasionally administered to provoke or modulate brain activity. Veterinary medicine also accounts for significant barbiturate utilization, especially in euthanasia procedures and as anesthetics in surgeries for companion and livestock animals. While no longer first-line for many conditions, the continued relevance of barbiturates is a testament to their unique pharmacological profile, making them irreplaceable in certain use-cases despite safer alternatives. These persistent clinical niches, especially in resource-constrained environments, ensure the global barbiturate market maintains a steady demand.

What is Shaping Regulatory and Manufacturing Trends in the Barbiturate Space?

The regulatory and manufacturing landscape of the barbiturate drugs market is evolving under the weight of tighter global controls, cost-efficiency demands, and innovation in pharmaceutical production. Due to their well-documented potential for abuse, overdose, and addiction, barbiturates are classified as controlled substances across most jurisdictions-ranging from Schedule II to IV under the U.S. Controlled Substances Act, depending on the specific drug and its intended use. This classification imposes rigorous requirements on manufacturing licenses, storage, prescribing limits, distribution logistics, and record-keeping, which in turn increases production complexity and compliance costs. Manufacturers are responding by centralizing their operations in regions with favorable regulatory frameworks while maintaining strict adherence to Good Manufacturing Practices (GMP). There is a trend towards contract manufacturing and outsourcing of active pharmaceutical ingredient (API) synthesis to reduce overhead while ensuring supply chain continuity. Simultaneously, advanced analytical technologies such as real-time release testing, PAT (process analytical technology), and AI-driven batch monitoring are enhancing consistency and reducing product recalls. In response to ongoing safety concerns, pharmaceutical companies are investing in the reformulation of traditional barbiturates into extended-release or lower-dose versions, aimed at reducing peak plasma concentrations and associated risks. Moreover, hybrid drug development, combining barbiturates with complementary agents to mitigate side effects, is receiving renewed research interest. Companies are also reexamining barbiturate scaffolds through the lens of modern medicinal chemistry, looking to develop analogs with improved safety and receptor selectivity. Together, these factors are shaping a modernized, more compliant, and innovation-focused production environment that is gradually reshaping the global barbiturate supply and delivery chain.

How Are Consumer Demographics and End-Uses Evolving in the Barbiturate Ecosystem?

Consumer demographics and application domains for barbiturate drugs are undergoing a quiet but impactful transformation driven by shifts in healthcare needs, geographic disparities, and changes in clinical practice. In high-income countries, the use of barbiturates is now highly restricted to specialized medical contexts, such as treatment-resistant epilepsy, induction of anesthesia for neurosurgery, and ICU sedation protocols. Patients requiring barbiturates in these environments are typically under the care of specialist physicians like neurologists, anesthesiologists, and critical care experts, ensuring controlled and monitored administration. In contrast, in low- and middle-income countries where medical budgets are constrained and healthcare infrastructure is still developing, barbiturates remain accessible and widely used due to their low cost and established track record. This divergence in prescribing patterns highlights the socioeconomic component influencing the barbiturate market’s global footprint. Another evolving domain is palliative care, where barbiturates are being employed to manage intractable pain and terminal agitation, especially in cancer patients or those with neurodegenerative diseases. In addition, the growing use of barbiturates in diagnostic neurology and in forensic toxicology labs maintains a steady demand from institutions and public health systems. The veterinary sector also plays a vital role in the barbiturate economy, with increasing global demand for humane euthanasia and surgical sedation solutions in both domestic and agricultural animals. Furthermore, the increase in chronic conditions requiring surgical interventions has elevated the need for fast-acting, reliable sedatives-sometimes fulfilled by short-acting barbiturates in resource-limited surgical settings. Emerging trends also show interest in tailoring barbiturate usage in niche psychiatric cases, such as catatonia and severe bipolar agitation, where rapid CNS depression may be therapeutically beneficial. These diverse applications across geographies, patient types, and medical disciplines continue to expand and redefine the consumer base of barbiturate drugs.

What Is Fueling the Growth in the Global Barbiturate Drugs Market?

The growth in the global barbiturate drugs market is driven by several factors related to clinical demand patterns, end-user preferences, and sector-specific dynamics. A primary growth driver is the persistent global burden of epilepsy, particularly in low-resource countries, where phenobarbital remains a first-line treatment due to its affordability, accessibility, and reliable efficacy profile. In markets where newer antiepileptic drugs are either unavailable or cost-prohibitive, barbiturates serve as the backbone of seizure management, especially in pediatric and adult populations with generalized tonic-clonic seizures. Another key driver is the role of barbiturates in critical care units, especially for induction of therapeutic coma, control of elevated intracranial pressure, and status epilepticus, where rapid and deep sedation is required-capabilities that many newer sedatives may not consistently offer. The veterinary pharmaceutical market is also contributing substantially to growth, driven by increasing pet ownership, rising expenditure on animal health, and standardized euthanasia protocols in animal shelters and farms, which often mandate barbiturate use. Moreover, the surge in surgical procedures globally, particularly in aging populations, necessitates a range of sedative options where short-acting barbiturates continue to find relevance. Technological advancements are also catalyzing market expansion, particularly the development of modified-release and lower-dose formulations that aim to mitigate traditional toxicity concerns while preserving therapeutic effectiveness. Regulatory shifts in emerging economies have created more accessible pathways for barbiturate approvals, expanding their market reach. Furthermore, the research community’s interest in exploring new therapeutic potentials of barbiturate analogs, especially for central nervous system disorders, is spurring innovation and patent activity, potentially opening new therapeutic avenues. Lastly, enhanced distribution infrastructure and digital supply chain integration are helping stabilize availability and reduce bottlenecks, ensuring that demand from healthcare and veterinary sectors is efficiently met. These combined factors are reinforcing the sustained growth trajectory of the global barbiturate drugs market.

SCOPE OF STUDY:

The report analyzes the Barbiturate Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs, Combination Drugs); Disease Type (Insomnia Disease, Epilepsy Disease, Sedation Disease, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Akorn Operating Company LLC
• Centurion Healthcare Pvt. Ltd.
• Eli Lilly and Company
• Ethypharm
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson
• Lundbeck A/S
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Mylan N.V.
• Par Pharmaceutical
• Pfizer Inc.
• Samarth Life Sciences Pvt. Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Barbiturate Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Seizure Disorders Throws the Spotlight on Barbiturate-Based Therapies
  • Tightening Regulations and Controlled Substance Policies Reshape Market Access and Compliance Costs
  • Expanding Off-Label Use in Psychiatry Drives Niche Demand for Barbiturate Formulations
  • Shift Toward Safer CNS Drugs Presents a Long-Term Challenge for Barbiturate Adoption
  • Global Shortages of Anesthetics Drive Temporary Uptick in Barbiturate Utilization
  • Growing Veterinary Use Cases Expand the Addressable Market for Barbiturate Products
  • Increasing Surgical Volumes Generate Demand for Fast-Acting Anesthesia Agents
  • Renewed Focus on Rare Disease Treatments Reopens Discussions on Barbiturate Utility
  • Cost-Effectiveness of Generic Barbiturates Strengthens Business Case in Low-Income Regions
  • Pharmaceutical Repackaging Trends Create New B2B Opportunities in Institutional Supply Chains
  • Telemedicine Expansion Spurs Online Prescriptions, Raising Distribution and Oversight Challenges
  • Mental Health Crisis Triggers Reassessment of Barbiturate Risk-Benefit Profiles
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Barbiturate Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Barbiturate Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Barbiturate Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Barbiturate Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Long-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Long-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Long-Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Short-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Short-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Short-Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Ultra-Short Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Ultra-Short Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Ultra-Short Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Insomnia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Insomnia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Insomnia Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Epilepsy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Epilepsy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Epilepsy Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Sedation Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Sedation Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Sedation Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• JAPAN
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• CHINA
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• EUROPE
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Barbiturate Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Barbiturate Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• FRANCE
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• GERMANY
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Barbiturate Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• INDIA
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Barbiturate Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Barbiturate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Barbiturate Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Barbiturate Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030
• AFRICA
  • Barbiturate Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Barbiturate Drugs by Drug - Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Barbiturate Drugs by Drug - Percentage Breakdown of Value Sales for Long-Acting Drugs, Short-Acting Drugs, Ultra-Short Acting Drugs and Combination Drugs for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Barbiturate Drugs by Distribution Channel - Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Barbiturate Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Other Distribution Channels and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Barbiturate Drugs by Disease Type - Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Barbiturate Drugs by Disease Type - Percentage Breakdown of Value Sales for Insomnia Disease, Epilepsy Disease, Sedation Disease and Other Disease Types for the Years 2014, 2025 & 2030

IV. COMPETITION